How Can Apo B and Insulin Contribute to ASCVD?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

We've talked about this so much with AMA 34, we covered what causes ASCVD. What we did is we combined a lot of these questions because there was a lot of people who are kind of wondering how they fit together. So it's a little bit related to Formula One, but not quite fully there. But on the plus side, like Formula One, you do like talking about cardiovascular disease.

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

In this “Ask Me Anything” (AMA) episode, Peter answers questions related to the leading cause of death in both men and women—atherosclerotic cardiovascular disease (ASCVD). He highlights the most important risk factors for ASCVD, such as apoB, LDL, hyperinsulinemia, and Lp(a), and explains the mechanism by which they confer risk and how these factors are interrelated. Peter also dives deep into the data around apoB to try to answer the question of how much residual risk is conferred for ASCVD through metabolic dysfunction once you correct for apoB. He also looks at the data around lifetime risk reduction of ASCVD in the context of low apoB.

If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #42 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

A racecar analogy for understanding atherosclerotic cardiovascular disease [2:00];
Defining and differentiating apoB and LDL-C [10:00];
The interrelated nature of insulin levels, apoB, triglycerides, and ASCVD parameters [13:00];
Another way that hyperinsulinemia plays a role in endothelial dysfunction [18:00];
Why Peter uses the oral glucose tolerance test (OGTT) with all patients [20:15];
Is there any evidence that hyperinsulinemia is an independent contributor to ASCVD? [23:00];
Thinking through risk in the context of high-fat diets resulting in improved metabolic metrics but with an elevation of apoB/LDL-C [27:30];
Thinking through risk in the context of low apoB but higher than normal triglyceride levels [32:15];
The importance of lowering apoB for reducing ASCVD risk [38:15];
Data on men and women with familial hypercholesterolemia that demonstrates the direct impact of high apoB and LDL-C on ASCVD risk [47:45];
Importance of starting prevention early, calcium scores, and explaining causality [52:30];
Defining Lp(a), its impact on ASCVD risk, and what you should know if you have high Lp(a) [56:30];
Lp(a) and ethnic differences in risk [1:00:30];
Why someone with elevated Lp(a) should consider being more aggressive with apoB lowering strategies [1:05:00];
Addressing the common feeling of hesitancy to taking a pharmacologic approach to lower ASCVD risk [1:07:15];
Peter’s take on the 2022 Formula 1 season and thoughts on 2023 [1:15:15]; and
More.